

Center for Medicaid, CHIP, and Survey & Certification**November 1, 2010****MEDICAID DRUG REBATE PROGRAM NOTICE****Release No. 156****For State Technical Contacts****INCORRECT DRUG PRODUCT INFORMATION REPORTED TO CMS****Unit Type and Units Per Package Size**

In accordance with section 1927 of the Social Security Act, labelers are required to submit and certify valid drug product data for a national drug code (NDC) before establishing and submitting quarterly pricing data. Drug product data includes both 9-digit and 11-digit NDC data fields.

Labelers are also responsible for submitting corrections to drug product data via the Drug Data Reporting for Medicaid (DDR) system. In an effort to make our reporting fields consistent and ensure uniformity in our drug product file, we request manufacturers to review their NDC's drug product data to ensure that one of the following eight unit types are used when submitting or updating product information:

For this Dosage	Apply This Unit Type	Abbreviation
Anti-Hemophilic Factor Injectables	Injectable Anti-Hemophilic Factor	AHF
All drugs dispensed in capsule form	Capsule	CAP
Drugs not identifiable by another unit; e.g., powder-filled vials, powder-filled ampules, powder-filled packets, and kits containing two or more items dispensed under one NDC and sold at a single price	Each	EA
Drugs measured by weight; e.g., creams, ointments, foams, powders, gels	Gram	GM
Drugs measured by liquid volume, e.g., oral or topical solutions, suspensions, lotions, sprays, liquid-filled vials, liquid-filled ampules, pre-filled syringes, all liquid ophthalmic products	Milliliter	ML
All suppositories whether dispensed individually or in dosage packets	Suppository	SUP
All drugs dispensed in tablet form	Tablet	TAB
All drugs dispensed as Transdermal Patches	Transdermal Patch	TDP

Further, we request that labelers review their drug product data to ensure that the Units Per Package Size (UPPS), currently defined as the total number of units in the smallest dispensable amount for the 11-digit NDC, is submitted accurately. This is in accordance with our instruction on how to report for the UPPS field in our Drug Product Data Web File Structure and Definition on our website at <http://www.cms.gov/MedicaidDrugRebateProgram/downloads/proddata.pdf> . Below is additional information on how to report the UPPS.

- When the pharmacist routinely dispenses the drug as it is packaged (an unbreakable quantity), you should show the UPPS as the actual size of the container.

Example: The unit type is a tablet, the NDC is for a package size holding 20 tablets, and the pharmacist is expected to dispense the entire container, rather than dispensing a smaller number of tablets from it. The appropriate entry in the UPPS field is "20."

- Where the number of units in the package size is such that the pharmacist is not expected to routinely dispense the entire package to the retail customer, (a breakable quantity), the appropriate entry in the UPPS field is "1".

Example: The unit type is a tablet, the package holds 500 tablets and the usual quantity prescribed by the doctor and dispensed by the pharmacist is fewer than 500 tablets. The UPPS entry should be "1".

In the future, we plan to post a file containing drug product data, without pricing data, at the 11-digit NDC level for labeler review on our website. We will be providing notification of such postings via our Medicaid Prescription Drug Policy & Reimbursement Updates mailing list. If you do not currently subscribe to this mailing list, please click on the following link to activate your subscription - https://subscriptions.cms.hhs.gov/service/subscribe.html?code=USCMS_589.

Drug Category and FDA Approval Date

In Manufacturer Release #80, we requested manufacturers to check the FDA website to ensure that the correct drug category is submitted to CMS. We are again requesting manufacturers to review the drug category of their reported products to ensure the accuracy of the data submitted to the CMS.

In general, those products that are approved under a New Drug Application (NDA) need to be reported to CMS as either single source (S) or innovator multiple source (I), and those products approved under an Abbreviated New Drug Application (ANDA) need to be reported to CMS as non-innovator multiple source (N).

We continue to encourage manufacturers to check the Food and Drug Administration's (FDA) NDC Directory, <http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm>, to determine whether the correct application number has been reported to the FDA for the product or to identify the correct drug category for the product based on the application number assigned to the product.

The FDA has also updated their Orange Book to reflect the FDA approval date by each specific product. Therefore, manufacturers may access the FDA's Orange Book, <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, and search by Application Number to

determine whether a product has been approved under an NDA (marked by an “N” in front of the application number) or ANDA (marked by an “A” in front of the application number), and whether the FDA approval date reported to CMS is the same date as listed in the Orange Book.

Furthermore, we have noticed that there has been some confusion as to when a brand name product should be reported as an “I” and when it should be reported as an “S.” We want to ensure that manufacturers are reporting the correct drug category for a brand name product. An “I” should be reported to CMS for a brand name drug that has a generic drug available. To know if a brand name drug has a generic drug available or not, you can access Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_d rug_name and search by the Application Number. If a generic drug is available, you will see the link to “Therapeutic Equivalents” in the middle of the “Drugs Details” page. Click on this link to see the generic and other therapeutically equivalent drug products. If there is no generic drug available for a brand name drug, then the brand name drug should be reported as an “S” to CMS.

If you determine that an incorrect drug category has been reported to CMS for a product, please e-mail RxDrugPolicy@cms.hhs.gov to request a drug category change for the product. Please note that changing the drug category from “S” to “I” does not require CMS prior approval; therefore, please access the DDR to do so.

Also, please note that under section 510 of the Federal Food, Drug and Cosmetic Act, as amended, with some limited exceptions, firms that manufacture, prepare, propagate, compound, or process drugs in the United States or that are offered for import into the United States are required to be registered with the FDA. *See* 21 U.S.C. §§ 360(b), (c), (d), and (i). Every person who registers must, at the time of initial registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution. 21 U.S.C. § 360(j)(1). *See also* 21 C.F.R. 207.20. Registering and listing updates must include drugs not previously listed (if any), and certain changes to information for previously listed drugs. 21 U.S.C. § 360(j)(2); 21 CFR 207.21(b), 207.30. Prescription drug products that are properly listed should appear in the FDA’s NDC Directory.

If you determine that your product is not currently listed or has been incorrectly listed with the FDA, please contact the FDA at eDRLS@fda.hhs.gov to update your product listing.

Penalties for Failure to Provide Timely Information and False Information

We would like to remind manufacturers that section 1927(b)(3)(C)(ii) states “any manufacturer with an agreement under this section that knowingly provides false information is subject to a civil money penalty in an amount not to exceed \$100,000 for each item of false information.” Therefore, we encourage manufacturers to carefully review their drug product data submissions, determine if any necessary change is needed, and take the necessary steps to make the change.

We ask that the labelers review and update their drug product data, and submit any correction or a change request, when necessary, in accordance with the guidance provided in this release.

Questions regarding Medicaid drug provisions can be submitted through the drug policy resource mailbox at RxDrugPolicy@cms.hhs.gov.

UPCOMING FILE FORMAT CHANGE TO COLLECT MONTHLY AMP UNITS

In accordance with section 1927 of the Social Security Act, as amended by the Affordable Care Act, manufacturers are required to report the total number of units that are used to calculate the monthly average manufacturer price (AMP) for each covered outpatient drug no later than 30 days after the last day of the month. Manufacturers are to report these units by the same unit type they use to calculate the monthly AMP.

We plan to require manufacturers to report the AMP units to CMS via the Medicaid Drug Data Reporting (DDR) system for the October 2010 reporting period. The new data field will be called "AMP Units". The AMP units should include the total sum of units for all package sizes included in the calculation of the AMP, and should be reported per product code (9-digit NDC level) for the monthly reporting period covered. For system implementation purposes, the data field will be: Numeric values, 14-digit field: 11 whole numbers, the decimal place (".") and two (2) decimal places; right-justified; zero-filled.

Once approval from the Office of Management and Budget is obtained, manufacturers will be notified via the Medicaid Prescription Drug Policy & Reimbursement Updates mailing list as to when the AMP unit field is available to report in the DDR system. If you do not currently subscribe to the Medicaid Prescription Drug Policy & Reimbursement Updates mailing list, please click on the following link to activate your subscription:

https://subscriptions.cms.hhs.gov/service/subscribe.html?code=USCMS_589

Questions regarding Medicaid drug provisions can be submitted to the drug policy resource mailbox at RxDrugPolicy@cms.hhs.gov.

Suzanne Bosstick /s/ for

Barbara Edwards
Director
Disabled and Elderly Health Programs Group

Attachment

cc:
Regional Administrators

**CMS RECORD SPECIFICATION
DDR MONTHLY PRICING DATA
TEXT FILE FOR TRANSFER TO CMS**

Source: Drug Manufacturers

Target: CMS

Field	Size	Position	Remarks
Record ID	1	1 - 1	Constant of "M"
Labeler Code	5	2 - 6	NDC #1
Product Code	4	7 - 10	NDC #2
Package Size	2	11 - 12	NDC #3
Month	2	13 - 14	MM
Year	4	15 - 18	YYYY
Average Mfr Price (AMP)	12	19 - 30	99999.999999
AMP Units	14	31 - 44	99999999999.99
Filler	21	45 - 51	spaces

TOPICAL INDEX – STATE RELEASES 1 - 156

TOPIC	RELEASE #
1A Drug Listing	11
Active Pharmaceutical Ingredient & Excipient Removal	155
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms CMS-304 & CMS-304a	57, 145
Affordable Care Act (ACA)	155
Allscripts Pharmaceuticals, Inc.	65, 68, 69
AMP Recalculations	107, 109, 110, 112, 140, 148, 149, 150
AMP to states	142
Monthly AMP Methodology (Manufacturer Assumptions)	146
Bankruptcy - Drug Labelers	19, 61, 68, 151
Best Price	
Effect of Sales to HMOs, etc.	137
To DSH Covered Entities	36
Under MPDIMA of 2003	128
Betaseron - Coverage & Reimbursement	38, 40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54, 55
Calphron	76, 79
Caverject Coverage	55
Closure During Federal Furloughs	57
Compendia	70, 141
Confidential Information Release	17
Constant Disputes by Drug Labelers	23
Contact Information	65, 92
CPI-U Information	09, 102, 147
Database Backup Files	140
Dataset Name Changes on Quarterly Rebate Tapes	41
Deficit Reduction Act of 2005 (DRA)	144
Deleted Products-No Termination Date	139
Depot Prices-TRRx	137
DESI Code Change	137, 140, 142, 144, 145, 146, 148, 149, 150, 151
Dipyridamole Issue	26
Dispute Resolution:	
Definition	19
E-Mail Address/Contacts	128, 155
Issues	55, 65, 71, 86, 108
Meetings	138, 140, 143, 145, 147
Process Stages	45
State Invoicing	152
Transfer of Function	121
Web Site	122
Workgroup Survey Results	42
Dispute Resolution Meetings	59, 151
Drug Category Change	61, 76
Drug Efficacy Study & Implementation (DESI):	
Change Effective Date	20
Change Schedule	18

TOPICAL INDEX – STATE RELEASES 1 - 156

TOPIC	RELEASE #
Effective Date Revisions	23, 24
(State Role In) DESI Process	148
DRUGDEX, a new compendium	70
Drug Emporium, Inc. Effective Date	65
Duplicate Discount/Rebate Mechanism Implementation	33
Effective Date(s) of Rebate Agreements	97
E-mail Address (Operations)	140
Enteral Nutritional Products - Coverage	30
Enteral Products	19
Eon Labs Product	117
Experimental Drugs - Coverage	43
Failure of Manufacturers to Notify States of	
Disputes or Pay Rebates	63
FDA/MDRI Data Match	107, 115
FDA Federal Register Notices	148, 149
Generic Substitution Laws	67
Goldline OTC Vitamin	102
Haldol Rebates	73, 75, 148
Heparin/Saline Flush Syringes & Other Non-Drug Products	132, 134, 136
Herceptin: Genentech New Product	85
HIPAA – Prescription Numbers	124
Hotline	53
HRSA Notice Published/Exclusion File	98, 101, 106
HRSA – NPI	144
Improper Rebate Withholding/Interest Implications	114
Index for Drug Rebate Notes	31
Information Sharing	57
Interest Calculation under Section V(b)	29, 88, 98
Interest:	
Failure to Pay	65
When PPAs are Submitted	121
Internet:	
Home Page/New Webpage Address	61, 85, 105, 117, 140
Prescription Reimbursement Information	123
Pharmacy Plus Demonstrations	123
Invoices:	
CMS R-144 (State Invoice) – Changes	143, 145, 146, 147, 149
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing	26
Remittance Advice Report Survey	35
Submission	19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	26, 32, 128, 132, 152
Lovenox Prefilled Syringes	91
LTE/IRS Drugs	26

TOPICAL INDEX – STATE RELEASES 1 - 156

TOPIC	RELEASE #
Magnetic Media	
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15, 23
Specification Revisions	14, 72, 73
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
MDR Technical E-mail Address	124, 137
Medicaid Drug Rebate Data Guide for States	146
Medical Supplies & Devices	03, 16, 26
Metric Conversion/Rounding	18
MMA of 2003	128, 130
Monthly AMP Units & File Record Layout	156
Multiple Package Size-Pricing Inconsistency	123
New Drug Determinations—Deletions from MDR	149, 150, 151
New Drug Products	41
New Rebate Agreement Status	23
Non-Drug Products Coverage	132, 134
(Non-Drug) Product Deletions	138, 139, 140, 142, 143, 144, 145, 146, 148, 149, 150, 151
Novartis Rounding All URAs Back to 1991	117
OBRA '93	40
OIG Reports/Reviews	120, 140
Ortho Evra Replacement Patch	134
Overpayments Due to AMP Recalculations	57, 107
Personnel:	
Changes	53, 124, 130, 139, 142
Relocation	52, 83
PHS Drug Pricing Program	44
Physician Administered Drugs	151
Point-of-Sale System (POS) in Pharmacies	85
Policy E-Mail Address	113, 117
Prior Authorization	55
Prior Period Adjustments	14, 16, 60, 87
Prior Period Adjustments - Eli Lilly & Company	37
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations CMS-2175-FC	126
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Prices, Late Submission	33
Quarterly Reporting - Form CMS-64.r	40
Quarterly Tape Submission to CMS	60, 72, 130
Quarterly Update File	14
Questions and Answers	65
Re-activated NDCs	145
Rebate Agreements:	

TOPICAL INDEX – STATE RELEASES 1 - 156

TOPIC	RELEASE #
Start Date Procedures	102
Separate/Supplemental	102
Rebate/Reimbursement Issues	64, 113
Rebates:	
Calculation Formula	07
Drugs Purchased Through the FSS	113
Less than Administrative Costs	40
Nonpayment	94
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
Recordkeeping Regulations	129
Regulation (CMS-2175-F)	136
Regulation (CMS-2238-FC)	
Preliminary Injunction	148
Rejection of State Records Matching LTE Drugs	41
Remittance Advice Report/Workgroup	48, 52, 53, 56
Rescission of Termination for Novopharm USA	39
S-TAG (Systems Technical Advisory Group)	85
Separate Rebate Agreements with Manufacturers	38, 113
Special Advisory Group	16
Special Study – Anti-Load Viral/AIDS Drugs	102
Standard Summary Record Format	13
State Application of the FUL Program	48
State Contact Information	23, 26, 41, 98
State Coverage:	
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Notification Method Change	148
State Pharmacy Assistance Programs	
Exemption From Medicaid Best Price	140
Revised Criteria	124
State Plan Amendment Requirement	47
State Quarterly URA Tape	
Labeler Contact Information	134
Mailing	133
State Responsibility - Terminated Drugs	19
State Utilization Data Study (SUDS)	33
T-bill Rates	83, 86, 132, 149, 150, 151
Technical Contact E-mail Address	140
Termination Date (NDC)	79
Terminated/Deleted Records	44
Termination From Program	55
Therapeutic Equivalency Code	64

TOPICAL INDEX – STATE RELEASES 1 - 156

TOPIC	RELEASE #
Timely Receipt of Tapes/Notices of Mailing	45
Tolerance Threshold Clarification	
For Interest	48
Rebate Amount Adjustments	44
Training Guide Obsolete	145
TRICARE Retail Pharmacy Benefit Plan	152
Unapproved Drugs—Deletions from DDR	151
Unit-Dose Packaging	15
Unit Per Package Size	03
Change for Boehringer Ingelheim Product	123
Unit Rebate Amount (URA):	
Additional Amounts in 3/1998 File	85
Edits	43
Erroneous Amounts	51
First-Time Reporting on State Tape	132
Incorrect Amounts for 1Q98	79, 80
Invoice when the Amount is Zero	44
New Rounding Method	98, 100, 101, 106
Recalculations	111
Unit Type:	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Reporting	156
Revisions	32, 83
Units Per Package Size	156
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Adjustments for Prior Calendar Quarters	67, 72
Receipt	29, 31
Utilization Data:	
Changes to Labelers	57
Corrections/Problems	18, 51, 72
Late Submission	18
Record Format	08, 13, 72, 147, 149
Set Naming Requirements	19
Tapes/Confirmation Letter	19, 30, 40, 45, 58, 72, 82
Transmitting Corrections/Adjustments to CMS	16, 40, 72
Utilization Discrepancy Report	139
Utilization Tape Record Specification	67, 72, 73, 98, 105
Vaccine:	
Deletions	26
Exclusions	19, 23
Policy Clarification	25
Viagra Coverage	81
Vitasert	64
Warrick Pharmaceuticals (Sodium Chloride Solution)	98

TOPICAL INDEX – STATE RELEASES 1 - 156

TOPIC	RELEASE #
Xenical Coverage	97
Y2K	72, 87